In the latest trading session,, 1.36 million Altimmune Inc (NASDAQ:ALT) shares changed hands as the company’s beta touched 0.07. With the company’s most recent per share price at $7.21 changed hands at -$0.33 or -4.38% at last look, the market valuation stands at $512.41M. ALT’s current price is a discount, trading about -105.83% off its 52-week high of $14.84. The share price had its 52-week low at $2.09, which suggests the last value was 71.01% up since then. When we look at Altimmune Inc’s average trading volume, we note the 10-day average is 2.67 million shares, with the 3-month average coming to 3.37 million.

Analysts gave the Altimmune Inc (ALT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ALT as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Altimmune Inc’s EPS for the current quarter is expected to be -0.37.

Altimmune Inc (NASDAQ:ALT) trade information

Instantly ALT was in red as seen in intraday trades today. With action 14.26%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -35.91%, with the 5-day performance at 14.26% in the green. However, in the 30-day time frame, Altimmune Inc (NASDAQ:ALT) is 13.19% up. Looking at the short shares, we see there were 22.24 million shares sold at short interest cover period of 7.94 days.

The consensus price target for the stock as assigned by Wall Street analysts is 25, meaning bulls need an upside of 71.16% from its recent market value. According to analyst projections, ALT’s forecast low is 12 with 35 as the target high. To hit the forecast high, the stock’s price needs a -385.44% plunge from its current level, while the stock would need to soar -66.44% for it to hit the projected low.

Altimmune Inc (ALT) estimates and forecasts

Data shows that the Altimmune Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -14.17% over the past 6 months, a 5.59% in annual growth rate that is considerably lower than the industry average of 19.40%. Year-over-year growth is forecast to reach -97.70% down from the last financial year.

The company’s revenue for the corresponding quarters a year ago was 362k and 37k respectively.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 35.74%. The 2024 estimates are for Altimmune Inc earnings to increase by 16.61%.

ALT Dividends

Altimmune Inc is expected to release its next quarterly earnings report on 2024-Nov-05.

Altimmune Inc (NASDAQ:ALT)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 0.80% of Altimmune Inc shares while 60.81% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 61.30%. There are 60.81% institutions holding the Altimmune Inc stock share, with STATE STREET CORP the top institutional holder. As of 2024-03-31, the company held 14.7996% of the shares, roughly 8.65 million ALT shares worth $88.05 million.

BLACKROCK INC. holds the second largest percentage of outstanding shares, with 6.9166% or 4.04 million shares worth $41.15 million as of 2024-03-31.

Among Mutual Funds, the top two as of Jun 30, 2024 were SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and iShares Russell 2000 ETF . With 2.23 shares estimated at $15.91 million under it, the former controlled 3.13% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.45% of the shares, roughly 1.74 shares worth around $12.43 million.